Thousands of stories

Efavirenz (brand names Sustiva and Stocrin) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.

For HIV infection that has not previously been treated, the United States Department of Health and Human Services Panel on Antiretroviral Guidelines currently recommends the use of efavirenz in combination with lamivudine/zidovudine (Combivir) or tenofovir/emtricitabine (Truvada) as the preferred NNRTI-based regimens in adults and adolescents.

Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.

The usual adult dose is 600 mg once a day. It is usually taken on an empty stomach at bedtime to reduce neurological and psychiatric adverse effects.

Efavirenz was combined with the popular HIV medication Truvada, which consists of tenofovir and emtricitabine, all of which are reverse transcriptase inhibitors. This combination of three medications approved by the U.S. Food and Drug Administration (FDA) in July 2006 under the brand name Atripla, provides HAART in a single tablet taken once a day. It results in a simplified drug regimen for many patients.

More on Wikipedia

Brand name: Sustiva
Generic name/category: Efavirenz, Non-nucleoside reverse transcriptase inhibitors, Alkynes, World Health Organization essential medicines
Company: Bristol-Myers Squibb BMS
Country/Market: USA, North America
Indication(s)/use: HIV combination therapy
Target: Healthcare Professionals (HCP)
Tagline: Thousands of stories
Medium: Web banner
Size/duration: 728X90
Publication/Aired: www.infectiousdiseasenews.com – September 2009
0 views
Sep 03, 2009

Visit AdPharm.net for more pharmaceutical ads